Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expiry date | 2024-11-15 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Rafael Holdings ( NYSE:RFL ) Third Quarter 2024 Results Key Financial Results Net loss: US$32.4m (loss widened by...
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potentialNEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while actively evaluating opportunities for strategic in
GAINESVILLE, Fla., May 30, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company’s pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type